Who can take Paxlovid?
Paxlovid is for individuals age 12 and older who have tested positive for COVID-19, are at increased risk of severe disease, and have developed COVID-19 symptoms in the last 5 days, even mild ones (such as runny nose or cough).
Qualifying conditions that put you at higher risk for severe disease include being over age 65, a current or former smoker, cancer, diabetes, and obesity, among others.
Get a free video consultation
Free telehealth consultations are available for eligible individuals 18 or older who are currently living in Massachusetts and insurance is not required. If you’re eligible, you’ll be connected with a clinician for a video consultation within 30 minutes. This service is available in English, Spanish, Haitian Creole, and Portuguese.
This service is not for medical emergencies or for individuals who are pregnant. If you are experiencing a medical emergency like having trouble breathing, please call 911.
Before getting started, make sure you have:
- A list of medications or vitamins you are taking,
- If you have kidney disease, a copy of your lab results from the last 3 months because the dose may need to be adjusted.
Clinicians are available every day from 8 a.m. to 10 p.m. EST.
This treatment is not a substitute for vaccination, which can prevent serious illness, hospitalization, and death. Learn more about getting vaccinated.
Learn more about COVID-19 treatments at mass.gov/CovidTreatments
Covid-19 Treatment Flyers
Covid-19 Treatment Flyer (English)
Covid-19 Treatment Flyer (Haitian Creole)
Covid-19 Treatment Flyer (Portuguese)
Covid-19 Treatment Flyer (Spanish)
Covid-19 Treatment Flyer (Multilingual in English, Spanish, Portuguese, and Haitian Creole)
Covid-19 Treatment Flyer (Multilingual in English, Spanish, Portuguese, and Khmer)
Need help?
Telehealth service is offered in collaboration with Color Health, Inc. If you need help, contact the Color Support Team at 844-352-6567 or email treatments@color.com from 9 a.m. to 8 p.m. EST.
Also, review Frequently Asked Telehealth Questions to learn more.